Ipsen Appoints Benoit Hennion as Executive Vice President and President, Primary Care
Ipsen (Euronext: IPN; ADR: IPSEY) today announced the appointment of Benoit Hennion as Executive Vice President and President, Primary Care, effective 13 March 2017. Mr. Hennion will report directly to David Meek, CEO of Ipsen, and will join the Executive Leadership Team. Jean Fabre, who has led the Primary Care business since 2011 will step down from the position in March 2017 to pursue a new career opportunity at another company.
David Meek, CEO of Ipsen, commented: “I would like to acknowledge the tremendous contribution made by Jean Fabre, who has been with our company for nearly a decade. It is my great pleasure to welcome his successor, Benoit Hennion, to the Executive Leadership Team as Executive Vice President and President, Primary Care. Throughout his 11 years at Ipsen, Benoit has consistantly demonstrated his strategic vision and ability to drive change. His thorough knowledge of Ipsen’s Primary Care portfolio, together with his broad, international leadership experience and indisputable leadership skills, will enable Benoit to play a central role in the on-going transformation of our global Primary Care operations into a sustainable business focused on meeting our patients’ needs.”
Mr. Hennion joined Ipsen in 2006 within the Corporate Strategic Planning team. In 2009, he became Primary Care Business Unit Head for France, and subsequently, in 2011, General Manager of France Operations (including both Specialty Care and Primary Care). Following the split between Specialty Care and Primary Care in 2014, Mr. Hennion was appointed Vice President, Asia-Pacific Specialty Care.
Mr. Hennion earned his MBA degree at ESSEC (Paris, France). Before joining Ipsen, he started his career at Societe Generale in the Czech Republic and then served for six years at the Paris office of Roland Berger Strategy Consultants.
Ipsen is a global specialty-driven pharmaceutical group with total sales close to €1.6 billion in 2016. Ipsen sells more than 20 drugs in more than 115 countries, with a direct commercial presence in more than 30 countries. Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its fields of expertise cover oncology, neurosciences and endocrinology (adult & pediatric). Ipsen’s commitment to oncology is exemplified through its growing portfolio of key therapies improving the care of patients suffering from prostate cancer, neuro-endocrine tumors, renal cell carcinoma and pancreatic cancer. Ipsen also has a significant presence in primary care. Moreover, the Group has an active policy of partnerships. Ipsen's R&D is focused on its innovative and differentiated technological platforms, peptides and toxins, located in the heart of the leading biotechnological and life sciences hubs (Les Ulis/Paris-Saclay, France; Slough/Oxford, UK; Cambridge, US). In 2016, R&D expenditures exceeded €200 million. The Group has more than 4,900 employees worldwide. Ipsen’s shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and are eligible to the “Service de Règlement Différé” (“SRD”). The Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I American Depositary Receipt (ADR) program, which trades on the over-the-counter market in the United States under the symbol IPSEY. For more information on Ipsen, visit www.ipsen.com .
Forward Looking Statement
The forward-looking statements, objectives and targets contained herein are based on the Group’s management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect the Group’s future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words "believes," "anticipates" and "expects" and similar expressions are intended to identify forward-looking statements, including the Group’s expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by the Group. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising product in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. The Group must face or might face competition from generic products that might translate into a loss of market share. Furthermore, the Research and Development process involves several stages each of which involves the substantial risk that the Group may fail to achieve its objectives and be forced to abandon its efforts with regards to a product in which it has invested significant sums. Therefore, the Group cannot be certain that favorable results obtained during pre-clinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the product concerned. There can be no guarantees a product will receive the necessary regulatory approvals or that the product will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the Group's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Group’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The Group also depends on third parties to develop and market some of its products which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to the Group’s activities and financial results. The Group cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of the Group’s partners could generate lower revenues than expected. Such situations could have a negative impact on the Group’s business, financial position or performance. The Group expressly disclaims any obligation or undertaking to update or revise any forward looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. The Group’s business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers.
The risks and uncertainties set out are not exhaustive and the reader is advised to refer to the Group’s 2015 Registration Document available on its website (www.ipsen.com ).
Didier Véron , +33 (0)1 58 33 51 16
Senior Vice-President, Public Affairs and Communication
Brigitte Le Guennec, +33 (0)1 58 33 51 17
Corporate External Communication Manager
Eugenia Litz , +44 (0) 1753 627721
Vice-President, Investor Relations
Côme de La Tour du Pin , +33 (0)1 58 33 53 31
Investor Relations Manager
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
DELTICOM/YOURTYRES.CO.UK16.3.2018 15:13 | pressemeddelelse
Summer Business with Yourtyres.co.uk: New Shop Feature and High-Performance Tyre Models
NJ-SAMSUNG-ELECTRONICS16.3.2018 13:02 | pressemeddelelse
Available Now: The Smartphone Made for the Way We Communicate Today, the Galaxy S9 and S9+
CONQUEST-GROUP16.3.2018 10:02 | pressemeddelelse
CONQUEST Group Announced the Expansion of its Asset Management Business with the Appointment of Philippe Taillardat to the Role of Director
ACCELSTOR16.3.2018 10:02 | pressemeddelelse
AccelStor All-Flash Solutions Unlock Data Possibilities for AI and Cloud
PA-WESTINGHOUSE-ELECTRIC16.3.2018 09:47 | pressemeddelelse
Westinghouse Completes First Major Decommissioning Work at a Nordic Commercial Nuclear Reactor
SEOUL-SEMICONDUCTOR16.3.2018 09:04 | pressemeddelelse
Lighting Manufacturer LTS Licht & Leuchten, Part of the Fargerhult Group, to Offer Selected Spot- & Downlights with Seoul Semiconductor’s SunLike Series Natural Spectrum LEDs
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum